Cargando…
A multi‐model approach to predict efficacious clinical dose for an anti‐TGF‐β antibody (GC2008) in the treatment of osteogenesis imperfecta
Osteogenesis imperfecta (OI) is a heterogeneous group of inherited bone dysplasias characterized by reduced skeletal mass and bone fragility. Although the primary manifestation of the disease involves the skeleton, OI is a generalized connective tissue disorder that requires a multidisciplinary trea...
Autores principales: | Mavroudis, Panteleimon D., Pillai, Nikhil, Wang, Qingping, Pouzin, Clemence, Greene, Benjamin, Fretland, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662198/ https://www.ncbi.nlm.nih.gov/pubmed/36004727 http://dx.doi.org/10.1002/psp4.12857 |
Ejemplares similares
-
Targeting TGF-β for treatment of osteogenesis imperfecta
por: Song, I-Wen, et al.
Publicado: (2022) -
Osteogenesis imperfecta
por: Vitturi, Bruno Kusznir, et al.
Publicado: (2018) -
Osteogenesis Imperfecta
por: Sam, Justin Easow, et al.
Publicado: (2017) -
Dentinogenesis imperfecta associated with osteogenesis imperfecta
por: Biria, Mina, et al.
Publicado: (2012) -
Excessive TGFβ signaling is a common mechanism in Osteogenesis Imperfecta
por: Grafe, Ingo, et al.
Publicado: (2014)